Cargando…

Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation

BACKGROUND: The development of factor VIII (FVIII) inhibitor is a severe complication during replacement therapy for hemophilia A patients. OBJECTIVES: We investigated the potential risk factors for FVIII inhibitor formation based on genome‐wide RNA‐sequencing and whole‐genome bisulfite sequencing a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wei, Lyu, Cuicui, Wang, Wentian, Xue, Feng, Chen, Lingling, Li, Huiyuan, Chi, Ying, Ma, Yueshen, Wu, Runhui, Fang, Yunhai, Zhang, Lei, Yang, Renchi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445143/ https://www.ncbi.nlm.nih.gov/pubmed/36090157 http://dx.doi.org/10.1002/rth2.12794

Ejemplares similares

Analysis of hospitalization of people with hemophilia—12 years of experience in a single center
por: Qu, Cuiyun, et al.
Publicado: (2022)

Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system
por: Lyu, Cuicui, et al.
Publicado: (2018)

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
por: Zhao, Yongqiang, et al.
Publicado: (2021)

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China
por: Yang, Renchi, et al.
Publicado: (2021)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Prediction of thrombosis in polycythemia vera: Development and validation of a multiple factor-based prognostic score system
por: Gu, Wenjing, et al.
Publicado: (2023)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020)

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
por: Liu, Guoqing, et al.
Publicado: (2023)

Hemophilia and sexual health: results from the HERO and B-HERO-S studies
por: Blamey, Greig, et al.
Publicado: (2019)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia
por: Xu, Richard Huan, et al.
Publicado: (2021)

methyl-ATAC-seq measures DNA methylation at accessible chromatin
por: Spektor, Roman, et al.
Publicado: (2019)

EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation
por: Lhoumaud, Priscillia, et al.
Publicado: (2019)

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Quality of Life in Hemophilia Complicated by Inhibitors
por: Bastani, P, et al.
Publicado: (2012)

Escape or Fight: Inhibitors in Hemophilia A
por: Merlin, Simone, et al.
Publicado: (2020)

Molecular Mechanisms of Inhibitor Development in Hemophilia
por: Tieu, Paul, et al.
Publicado: (2020)

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
por: Li, Zekun, et al.
Publicado: (2021)

Cost-effective DNA methylation profiling by FML-seq
por: Foley, Joseph W., et al.
Publicado: (2023)

Cost-effective DNA methylation profiling by FML-seq
por: Foley, Joseph W, et al.
Publicado: (2023)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

T2 mapping in the quantitative evaluation of articular cartilage changes in children with hemophilia: A pilot study
por: Zhang, Ningning, et al.
Publicado: (2019)

P1617: A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A PEGYLATED-RECOMBINANT HUMAN COAGULATION FACTOR VIII-FC FUSION PROTEIN WITH HALF-LIFE IN PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, Feng, et al.
Publicado: (2023)

Integrated analysis of mRNA-seq and miRNA-seq reveals the advantage of polyploid Solidago canadensis in sexual reproduction
por: Wu, Miao, et al.
Publicado: (2021)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Identification of DNA methylation-regulated differentially expressed genes in RA by integrated analysis of DNA methylation and RNA-Seq data
por: Zhang, Runrun, et al.
Publicado: (2022)

Development of inhibitors in hemophilia A: An illustrated review
por: Jardim, Letícia Lemos, et al.
Publicado: (2020)

Costs of the management of hemophilia A with inhibitors in Spain
por: Bonanad, Santiago, et al.
Publicado: (2021)

The impact of inhibitors on the quality of life in patients with hemophilia
por: Haghpanah, Sezaneh, et al.
Publicado: (2023)

Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1
por: Gao, Yuchen, et al.
Publicado: (2023)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
por: Sun, Jie, et al.
Publicado: (2022)

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
por: Saba, Hussain I, et al.
Publicado: (2011)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

MIRA-seq for DNA methylation analysis of CpG islands
por: Jung, Marc, et al.
Publicado: (2015)

Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis
por: Lyu, Shi-Yi, et al.
Publicado: (2023)

Integrated Analysis of Hi-C and RNA-Seq Reveals the Molecular Mechanism of Autopolyploid Growth Advantages in Pak Choi (Brassica rapa ssp. chinensis)
por: Wu, Huiyuan, et al.
Publicado: (2022)

MicroRNA-150 inhibitors enhance cell apoptosis of melanoma by targeting PDCD4
por: Wan, Jianji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_inojo0hcfftmjrd5oe4n541dg7